Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
CSCastle Biosciences, Inc. logo

Castle Biosciences, Inc. (CSTL)

NASDAQ Global Market · Currency in USD
$33.08 ▼ -0.11 (-0.33%)
At close: Oct 23, 4:00 PM ET. Market closed.
$33.08 ▲ +0.00 (+0.00%)
After hours: Oct 23, 4:37 PM ET

Summary

Previous Close
$33.19
Open
$33.41
Day's Range
$32.69 – $33.62
52 Week Range
$17.72 – $44.28
Volume
203,016
Avg. Volume
388,953
Market Cap
$1.01B
Beta (5Y Monthly)
0.95
PE Ratio (TTM)
--
EPS (TTM)
-$0.64
Earnings Date
Nov 5, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$38.75

Profile: Castle Biosciences, Inc.

Sector
Healthcare
Industry
Medical - Diagnostics & Research
Full-time employees
1,002
CEO
Derek J. Maetzold

Castle Biosciences, Inc. functions as a commercial-stage diagnostics firm, with its primary objective being the provision of both diagnostic and prognostic testing services, specifically targeting various dermatological cancers. Their flagship product, DecisionDx-Melanoma, represents an advanced multi-gene expression profile (GEP) assay engineered to assess the probability of metastasis in patients afflicted with invasive cutaneous melanoma. In addition to their leading solution, the company has created several other specialized, proprietary tests.

Earnings

Next report: Thu, Nov 5, 2026
EPS estimate -$0.35 · Revenue est. $92.41M
DateEst.Actual
Jul 30, 2026-$0.41-$0.07Beat
May 6, 2026-$0.49-$0.49Beat
Feb 26, 2026-$0.23-$0.08Beat
Nov 3, 2025-$0.34-$0.02Beat
Aug 4, 2025-$0.51$0.15Beat
May 5, 2025-$0.08-$0.90Miss

Analyst view

Consensus price target
$38.75 ▲ +17.1%
Range $35.00 – $44.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on CSTL and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.